Superantigen-activated mononuclear cells induce apoptosis in transitional cell carcinoma

Anticancer Research

Volumn 25, Issue 5, 2005, Pages 3565-3573

  Perabo, Frank G E ^a,c   Willert, Patricia L ^a   Wirger, Andreas ^b   Schmidt, Doris H ^a   Von Ruecker, Alexander ^a   Mueller, Stefan C ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

^c NONE   (Germany)

Author keywords

Apoptosis; Bladder cancer; Fas ligand; Staphylococcal enterotoxin B; Superantigen

Indexed keywords

BCG VACCINE; CYTOKINE; FAS ANTIGEN; FAS LIGAND; GAMMA INTERFERON; INTERLEUKIN 2; STAPHYLOCOCCUS ENTEROTOXIN B; SUPERANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; LYMPHOCYTE ACTIVATION; MONONUCLEAR CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; TRANSITIONAL CELL CARCINOMA;

ANTIGENS, CD95; APOPTOSIS; CARCINOMA, TRANSITIONAL CELL; CELL LINE, TUMOR; CYTOKINES; ENTEROTOXINS; FAS LIGAND PROTEIN; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; LEUKOCYTES, MONONUCLEAR; MEMBRANE GLYCOPROTEINS; SUPERANTIGENS; URINARY BLADDER NEOPLASMS;

EID: 23344452992     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Shelley MD, Court JB, Kynaston H, Wilt TJ, Fish RG and Mason M: Intravesical Bacillus Calmette-Guerin in Ta and T1 bladder cancer (Cochrane Review). Cochrane Database Syst Rev 4: CD001986, 2000.
2. Thanhauser A, Bohle A, Schneider B, Reiling N, Mattern T, Ernst M, Flad HD and Ulmer AJ: The induction of bacillus-Calmette-Guerin-activated killer cells requires the presence of monocytes and T-helper type-1 cells. Cancer Immunol Immunother 40: 103-108, 1995.
3. Patard JJ, Muscatelli-Groux B, Saint F, Popov Z, Maille P, Abbou C and Chopin D: Evaluation of local immune response after intravesical bacille Calmette-Guerin treatment for superficial bladder cancer. Br J Urol 78: 709-714, 1996.
4. Luo Y, Chen X, Downs TM, DeWolf WC and O'Donnell MA: IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guerin immunotherapy. J Immunol 162: 2399-2405, 1999.
5. Baker MD and Acharya KR: Superantigens: structure-function relationships. Int J Med Microbiol 293: 529-537, 2004.
6. Petersson K, Forsberg G and Walse B: Interplay between superantigens and immunoreceptors. Scand J Immunol 59: 345-355, 2004.
7. Dohlsten M, Sundstedt A, Bjorklund M, Hedlund G and Kalland T: Superantigen-induced cytokines suppress growth of human colon-carcinoma cells. Int J Cancer 54: 482-488, 1993.
8. Lando PA, Hedlund G, Dohlsten M and Kalland T: Bacterial superantigens as anti-tumor agents: induction of tumor cytotoxicity in human lymphocytes by staphylococcal enterotoxin A. Cancer Immunol Immunother 33: 231-237, 1991.
9. Lando PA, Dohlsten M, Ohlsson L and Kalland T: Tumor-reactive superantigens suppress tumor growth in humanized SCID mice. Int J Cancer 62: 466-471, 1995.
10. Litton MJ, Dohlsten M, Lando PA, Kalland T, Ohlsson L, Andersson J and Andersson U: Antibody-targeted superantigen therapy induces tumor-infiltrating lymphocytes, excessive cytokine production, and apoptosis in human colon carcinoma. Eur J Immunol 26: 1-9, 1996.
11. Litton MJ, Dohlsten M, Rosendahl A, Ohlsson L, Sogaard M, Andersson J and Andersson U: The distinct role of CD4+ and CD8+ T-cells during the anti-tumor effects of targeted superantigens. Br J Cancer 81: 359-366, 1999.
12. Ochi A, Migita K, Xu J and Siminovitch K: In vivo tumor immunotherapy by a bacterial superantigen. J Immunol 151: 3180-3186, 1993.
13. Pulaski BA, Terman DS, Khan S, Muller E and Ostrand-Rosenberg S: Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model. Cancer Res 60: 2710-2715, 2000.
14. Rosendahl A, Kristensson K, Carlsson M, Skartved NJ, Riesbeck K, Sogaard M and Dohlsten M: Long-term survival and complete cures of B16 melanoma-carrying animals after therapy with tumor-targeted IL-2 and SEA. Int J Cancer 81: 156-163, 1999.
15. Shimizu M, Yamamoto A, Nakano H and Matsuzawa A: Augmentation of antitumor immunity with bacterial superantigen, Staphylococcal enterotoxin B-bound tumor cells. Cancer Res 56: 3731-3736, 1996.
16. Forsberg G, Ohlsson L, Brodin T, Bjork P, Lando PA, Shaw D, Stern PL and Dohlsten M: Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen. Br J Cancer 55: 129-136, 2001.
17. Bonfoco E, Stuart PM, Brunner T, Lin T, Griffith TS, Gao Y, Nakajima H, Henkart PA, Ferguson TA and Green DR: Inducible nonlymphoid expression of Fas ligand is responsible for superantigen-induced peripheral deletion of T cells. Immunity 9: 711-720, 1998.
18. Boshell M, McLeod J, Walker L, Hall N, Patel Y and Sansom D: Effects of antigen presentation on superantigen-induced apoptosis mediated by Fas/Fas ligand interactions in human T cells. Immunology 87: 586-592, 1996.
19. Perabo FGE, Kamp S, Schmidt D, Lindner H, Steiner G, Mattes RH, Wirger A, Pegelow K, Von Ruecker A, Albers P and Müller SC: Bladder cancer cells acquire competent mechanisms to escape apoptosis and immune surveillance in the course of malignant transformation. Br J Cancer 84: 1330-1338, 2001.
20. Alderson MR, Tough TW, Davis-Smith T, Braddy S, Falk B, Schooley A, Goodwin RG, Smith CA, Ramsdell F and Lynch DH: Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med 181: 71-77, 1995.
21. Sperber K, Bauer J, Pizzimenti A, Najfeld V and Mayer L: Identification of subpopulations of human macrophages through the generation of human macrophage hybridomas. J Immunol Methods 729: 31-40, 1990.
22. Lamm DL, Stogdill VD, Stogdill BJ and Crispen RG: Complications of Bacillus Calmette-Guerin immunotherapy in 1,278 patients with bladder cancer. J Urol 135: 272-274, 1986.
23. Berry DL, Blumenstein BA, Magyarym DL, Lamm DL and Crawford ED: Local toxicity patterns associated with intravesical bacillus Calmette-Guerin: A Southwest Oncology Group Study. Int J Urol 3: 98-101, 1995.
24. Kagi D, Vignaux F, Ledermann B, Burki K, Depraetere V, Nagata S, Hengartner H and Golstein P: Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxcicity. Science 265: 528-530, 1994.
25. Nagata S: Apoptosis by death factor. Cell 88: 355-365, 1997.
26. Knox PG, Milner AE, Green NK, Eliopoulos AG and Young LS: Inhibition of metalloproteinase cleavage enhances the cytotoxicity of Fas ligand. J Immunol 170: 677-685, 2003.
27. Pinkoski MJ, Droin NM and Green DR: Tumor necrosis factor alpha up-regulates non-lymphoid Fas-ligand following superantigen-induced peripheral lymphocyte activation. J Biol Chem 277: 42380-42385, 2002.
28. Nguyen T and Russell J: The regulation of FasL expression during activation-induced cell death (AICD). Immunology 103: 426-434, 2001.
29. Lacana E and D'Adamio L: Regulation of Fas ligand expression and cell death by apoptosis-linked gene 4. Nat Med 5: 542-547, 1999.
30. Kappler J, Kotzin B, Herren L, Gelfand EW, Bigler RD, Boylston A, Carrel S and Marrack P: Vbeta- specific Stimulation of human T cells by staphylococcal endotoxins. Science 244: 811-813, 1989.
31. Kum WW, Cameron SB, Hung RW, Kalyan S and Chow AW: Temporal sequence and kinetics of proinflammatory and antiinflammatory cytokine secretion induced by toxic shock syndrome toxin 1 in human peripheral blood mononuclear cells. Infect Immun 69: 7544-7549, 2001.
32. Hedlund G, Dohlsten M, Lando PA and Kall T: Staphylococcal enterotoxins direct and trigger CTL killing of autologous HLA-DR mononuclear leucocytes and freshly prepared leukemia cells. Cell Immunol 729: 426-434, 1990.
33. Fuller CL and Braciale VL: Selective induction of CD8+ cytotoxic T lymphocyte effector function by staphylococcus enterotoxin B. J Immunol 161: 5179-5186, 1998.
34. Roberts AI, Blumberg RS, Christ AD, Brolin RE and Ebert EC: Staphylococcal enterotoxin B induces potent cytotoxic activity by intraepithelial lymphocytes. Immunology 101: 185-190, 2000.